DE60138572D1 - Methoden und pharmazeutische zusammensetzungen zur wundheilung - Google Patents

Methoden und pharmazeutische zusammensetzungen zur wundheilung

Info

Publication number
DE60138572D1
DE60138572D1 DE60138572T DE60138572T DE60138572D1 DE 60138572 D1 DE60138572 D1 DE 60138572D1 DE 60138572 T DE60138572 T DE 60138572T DE 60138572 T DE60138572 T DE 60138572T DE 60138572 D1 DE60138572 D1 DE 60138572D1
Authority
DE
Germany
Prior art keywords
methods
pharmaceutical compositions
wound healing
pharmaceutical composition
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138572T
Other languages
English (en)
Inventor
Tamar Tennenbaum
Sanford Sampson
Toshio Kuroki
Addy Alt
Shlomzion Shen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bar Ilan University
Original Assignee
Bar Ilan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar Ilan University filed Critical Bar Ilan University
Application granted granted Critical
Publication of DE60138572D1 publication Critical patent/DE60138572D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60138572T 2000-07-31 2001-07-23 Methoden und pharmazeutische zusammensetzungen zur wundheilung Expired - Lifetime DE60138572D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62997000A 2000-07-31 2000-07-31
PCT/IL2001/000675 WO2002009639A2 (en) 2000-07-31 2001-07-23 Methods and pharmaceutical compositions for healing wounds

Publications (1)

Publication Number Publication Date
DE60138572D1 true DE60138572D1 (de) 2009-06-10

Family

ID=24525225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138572T Expired - Lifetime DE60138572D1 (de) 2000-07-31 2001-07-23 Methoden und pharmazeutische zusammensetzungen zur wundheilung

Country Status (12)

Country Link
US (2) US7402571B2 (de)
EP (1) EP1383540B1 (de)
JP (2) JP2004536018A (de)
AT (1) ATE429925T1 (de)
AU (2) AU2001284364B2 (de)
CA (1) CA2416788A1 (de)
DE (1) DE60138572D1 (de)
DK (1) DK1383540T3 (de)
HK (1) HK1059738A1 (de)
IL (1) IL154210A0 (de)
WO (1) WO2002009639A2 (de)
ZA (1) ZA200300708B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
ATE429925T1 (de) 2000-07-31 2009-05-15 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7771931B2 (en) * 2001-09-06 2010-08-10 The General Hospital Corporation Methods for diagnosing and treating diseases and conditions associated with protein kinase Cλ
CN101850108A (zh) * 2003-07-15 2010-10-06 巴尔-伊兰大学 用于愈合创伤的方法和药物组合物
ATE529125T1 (de) * 2003-08-07 2011-11-15 Healor Ltd Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
JP5324781B2 (ja) * 2004-06-14 2013-10-23 ビーエーエスエフ、ビューティー、ケア、ソルーションズ、フランス、エスエーエス Ｐｔｈ断片含有化粧品
CA2625674C (en) * 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
FR2907683A1 (fr) * 2006-10-27 2008-05-02 De Potter Philippe Viseux Composition medicale pour cicatrisation des plaies et pansements permettant son application
NZ582556A (en) * 2007-07-30 2013-02-22 Healor Ltd Pharmaceutical composition for treating wounds and related methods
CA2789972A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
CN105308052B (zh) 2013-04-18 2018-07-10 Q生物有限公司 用于伤口愈合的方法和组合物
CA2976096C (en) 2014-02-20 2023-03-14 University Of Notre Dame Du Lac Substituted 2-[(4-phenoxyphenyl)sulfonylmethyl]thiirane as selective matrix metalloproteinase inhibitors
US10357546B2 (en) 2014-09-19 2019-07-23 University Of Notre Dame Du Lac Acceleration of diabetic wound healing
WO2016149187A1 (en) * 2015-03-13 2016-09-22 Joslin Diabetes Center, Inc. Methods to accelerate wound healing in diabetic subjects
US20180256537A1 (en) * 2015-09-23 2018-09-13 Tapan K. Khan Methods for survival and rejuvenation of dermal fibroblasts using pkc activators
EP3595680A1 (de) * 2017-03-17 2020-01-22 Rutgers, The State University of New Jersey Zusammensetzungen und verfahren zur wundheilung
CN115531415B (zh) * 2022-12-01 2023-03-28 山东大学 一种i-CS/HAp-NK复合体及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119914A (en) * 1871-10-17 Improvement in harness-trimmings
US4673649A (en) 1983-07-15 1987-06-16 University Patents, Inc. Process and defined medium for growth of human epidermal keratinocyte cells
WO1985005036A1 (en) 1984-04-30 1985-11-21 The Trustees Of Columbia University In The City Of Topical treatment of diabetes with insulin and penetrant enhancer applied to the skin and covered by a patch
EP0223977B1 (de) 1985-11-25 1990-10-10 Wako Pure Chemical Industries, Ltd. Farbentwicklungsmethode in klinischen Untersuchungen
US4833257A (en) 1986-07-28 1989-05-23 Arizona Board Of Regents Compositions of matter and methods of using same
JPS63303929A (ja) * 1987-06-04 1988-12-12 Kanji Izumi 創傷治療剤
US5700450A (en) 1988-03-30 1997-12-23 The Trustees Of Boston University Methods for enhancing melanin synthesis in melanocytes using diacyglycerols and uses thereof
US5137734A (en) 1989-03-22 1992-08-11 Dana Farber Cancer Institute Angiogenic monoglycerides
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
US5423778A (en) 1989-12-14 1995-06-13 Elof Eriksson System and method for transplantation of cells
ES2136620T3 (es) 1991-04-19 1999-12-01 Lds Technologies Inc Formulaciones de microemulsiones convertibles.
JPH0543453A (ja) * 1991-08-20 1993-02-23 Sumitomo Pharmaceut Co Ltd 創傷治癒促進用局所用徐放性製剤
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
HUT67319A (en) * 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
AU3062392A (en) 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
EP0679402B1 (de) 1994-04-25 2003-09-10 Japan Science and Technology Corporation Hybridgel, das eine biologisch aktive Substanz sekretiert
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
JP3091113B2 (ja) * 1994-11-22 2000-09-25 科学技術振興事業団 生理活性物質分泌性のハイブリッド型ゲル
EP0871474B2 (de) 1994-12-29 2011-09-21 Ferring International Center S.A. Herstellung von humaninsulin
AUPN089295A0 (en) 1995-02-02 1995-03-02 International Diabetes Institute Treatment of diabetic neuropathy
ES2200150T3 (es) 1996-01-23 2004-03-01 The Board Of Trustees Of The Leland Stanford Junior University Procedimiento de cribaje de peptidos efectores transdominantes y moleculas de arn.
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
JPH10265405A (ja) * 1997-03-19 1998-10-06 Masaaki Nanbara インスリン含有の皮膚外用製剤
WO1999018920A1 (en) 1997-10-16 1999-04-22 Deguang Zhu A new powerful cosmetic or pharmaceutical composition
WO1999035283A1 (en) * 1997-12-15 1999-07-15 Beth Israel Deaconess Medical Center Methods and reagents for modulating cell motility
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
JP2002500196A (ja) * 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ 安定化させたインスリン組成物
US6096288A (en) 1998-10-12 2000-08-01 Mobil Oil Corporation Synthesis of the cubic mesoporous molecular sieve MCM-48
US6541447B1 (en) 1999-09-01 2003-04-01 B & M Healthcare Technologies, Inc. Wound healing composition and method for use thereof
EP1272231A1 (de) 2000-04-06 2003-01-08 University Technology Corporation Zusammensetzungen und verfahren zur förderung der wundheilung
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
ATE429925T1 (de) 2000-07-31 2009-05-15 Univ Bar Ilan Methoden und pharmazeutische zusammensetzungen zur wundheilung
US6673603B2 (en) 2000-09-01 2004-01-06 Modex Therapeutiques, S.A. Cell paste comprising keratinocytes and fibroblasts
US20020119914A1 (en) 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
CN1265792C (zh) 2001-03-08 2006-07-26 肯塔基大学研究基金会 含有8－22个碳原子的烷基链的烟酸烷基酯在制备提高受试者瘦素水平的药物中的用途

Also Published As

Publication number Publication date
EP1383540B1 (de) 2009-04-29
US20030144180A1 (en) 2003-07-31
HK1059738A1 (en) 2004-07-16
CA2416788A1 (en) 2002-02-07
DK1383540T3 (da) 2009-08-24
WO2002009639A2 (en) 2002-02-07
JP5385321B2 (ja) 2014-01-08
EP1383540A2 (de) 2004-01-28
JP2011140505A (ja) 2011-07-21
JP2004536018A (ja) 2004-12-02
ATE429925T1 (de) 2009-05-15
WO2002009639A3 (en) 2003-11-06
US7402571B2 (en) 2008-07-22
IL154210A0 (en) 2003-07-31
US20030017969A1 (en) 2003-01-23
EP1383540A4 (de) 2004-06-30
AU8436401A (en) 2002-02-13
ZA200300708B (en) 2005-02-23
AU2001284364B2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
ATE429925T1 (de) Methoden und pharmazeutische zusammensetzungen zur wundheilung
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
SE0100568D0 (sv) Compounds
BRPI0418245B8 (pt) composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
CA2503810A1 (en) Therapeutic agent for fibromyalgia
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
IL151628A0 (en) Combination therapies with vascular damaging activity
TWI264311B (en) Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
SE0102440D0 (sv) New compound
SE0100566D0 (sv) Compounds
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
SE0101692D0 (sv) Compounds
EE200200549A (et) Jagatud doosi teraapia veresooni kahjustava aktiivsusega
SE9900190D0 (sv) New compounds
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
ATE284696T1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition